Research Paper Volume 11, Issue 22 pp 10644—10663

Figure 2. MYSM1 knockdown promotes proliferation and suppresses senescence of prostate cancer cells. (A–B) MYSM1 expression levels in CRPC cell lines (C4-2, 22Rv1) stably expressing shRNA targeting MYSM1 (shMYSM1) or negative control (shNC) were detected by qRT-PCR (A) and Western blot (B) analyses. Data are shown as mean ± SEM of 3 replicates. ** P < 0.01 and *** P < 0.001 (one-way ANOVA test). (C) Proliferation of shNC/shMYSM1-treated C4-2/22Rv1 cells was evaluated by MTT assay. Data are shown as mean ± SEM of 3 replicates. (D) Flow cytometry analysis of cell cycle in C4-2/22Rv1 cells treated with shNC/shMYSM1. Data are shown as mean ± SD of 3 replicates. ** P < 0.01 and *** P < 0.001 (Student’s t-test). (E) Representative images of SA-β-gal staining in C4-2/22Rv1 cells treated with shNC/shMYSM1. Scale bars are 25 μm. Data are shown as mean ± SD of 3 replicates. *** P < 0.001 and **** P < 0.0001 (Student’s t-test). (F) Correlation of MYSM1 with CDK4, CCND3, CCNE1 and RB1 mRNA levels in prostate cancers. Data were collected from TCGA database and analyzed via LinkedOmics bioinformatics. Pearson correlation coefficients and significance levels are indicated.